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COVID-19 mortality in hospitalized cancer patients is not 1 
significantly affected by chemotherapy or other anti-cancer 2 
treatments.  3 
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Abstract 34 
 35 
Background 36 
Individuals with cancer, particularly those who are receiving systemic anti-cancer treatments, have been 37 
postulated to be at increased risk of mortality from SARS-CoV-2 related coronavirus disease (COVID-19). 38 
This conjecture has considerable impact on the treatment of cancer patients and large, multi-centre data 39 
to support this assumption is lacking due to the contingencies of the pandemic.  40 
 41 
Methods 42 
The cancer community of the United Kingdom (UK) has launched the UK Coronavirus Cancer Monitoring 43 
Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time 44 
reports to frontline doctors about the effect of COVID-19 on cancer patients.  45 
 46 
Findings 47 
An analysis of the first 800 cancer patients with symptomatic COVID-19 disease entered into the 48 
UKCCMP registry has been performed. Approximately half of these patients have a mild COVID-19 49 
disease course (52%). Mortality was observed in 226 patients (28%) and risk of death was significantly 50 
associated with advancing patient age, sex (M>F) and the presence of other co-morbidities. 51 
Approximately one third had received cytotoxic chemotherapy within 4 weeks prior to testing positive for 52 
COVID-19. After adjusting for age, sex and comorbidities, recent receipt of chemotherapy had no 53 
significant effect on mortality from COVID-19 disease, when compared to cancer patients who had not 54 
received recent chemotherapy. No significant effect on mortality was also observed for patients with recent 55 
immunotherapy, hormonal therapy, targeted therapy or radiotherapy use.  56 
 57 
Interpretation 58 
Mortality from COVID-19 in cancer patients appears to be principally driven by age, sex and co-59 
morbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other 60 
anti-cancer treatment are at significantly increased risk of mortality from COVID-19 disease compared to 61 
those not on active treatment.   62 
  63 
Introduction 64 
 65 
It is clear from data arising from the Office for National Statistics that the risk of morbidity and mortality 66 
from COVID-19 disease as a consequence of SARS-CoV-2 infection is not uniform across the population. 67 
Cancer patients on systemic anti-cancer treatments have been generally assumed by many to be at a 68 
higher risk than their counterparts who are not currently receiving anti-cancer treatment. The evidence to 69 
support this claim is scanty and limited to retrospective series arising from China, the epicentre of the 70 
current pandemic, and involving very small numbers of patients. 1,2,3 However despite these severe 71 
limitations, the promulgation of this hypothesis has led to widespread, global changes to chemotherapy 72 
and anti-cancer treatment prescribing patterns. 4 In a global health emergency, it is critical that oncologists 73 
secure evidence from a larger dataset, which can then inform their risk benefit analyses for individual 74 
patients in terms of the use of anti-cancer treatments. 5,6 75 
 76 
On 18th March 2020, we launched the UK Coronavirus Cancer Monitoring Project (UKCCMP) with 77 
widespread support across our national cancer network. 7,8 Within 5 weeks the UKCCMP had generated 78 
the largest prospective database and interrogation of COVID-19 disease  in cancer patients generated to 79 
date. Here we describe the clinical and demographic characteristics and COVID-19 outcomes in this 80 
cohort of patients with cancer and symptomatic COVID-19 and attempt to assess how the presence of 81 
cancer and the receipt of cytotoxic chemotherapy and other anti-cancer treatments impacts upon COVID-82 
19 disease phenotype. 83 
  84 
Methods 85 
 86 
Study Design and Participants 87 
The UKCCMP database of United Kingdom (UK) cancer patients with a COVID-19 infection was launched 88 
with the support of the UK oncology professional bodies, including the Association of Cancer Physicians 89 
(ACP), The Royal College of Radiologists (RCR), the National Oncology Trainees Research Collaborative 90 
for Healthcare Research (NOTCH), patient support groups including Macmillan Cancer Support, charities 91 
including Action Radiotherapy and our national research body, Cancer Research UK (CRUK). 9,10 It was 92 
designed as a Public Health Surveillance registry to support rapid clinical decision-making, in accordance 93 
with the UK Policy Framework for Health and Social Care Research, the UK National Research Ethics 94 
Service and the UK Governance Arrangement for Research Ethic Committees. At an institutional level, 95 
this cohort study was approved according to local information governance processes. All patients with 96 
active cancer and presenting to our network of cancer centres from March 18th 2020 to April 26th 2020 97 
with COVID-19 were eligible for enrolment into the UKCCMP. In keeping with international practice, 98 
patients were deemed to have COVID-19 if there was a positive SARS-CoV-2 Real-Time Reverse 99 
Transcription Polymerase Chain Reaction (RT-PCR) assay test from a throat/nose swab. Patients with a 100 
radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test were not included in this 101 
analysis. As such, these patients are, by definition, symptomatic, requiring secondary care review for 102 
potential hospitalization. They were not part of a proactive surveillance program. ‘Patients with active 103 
cancer’ was defined as those with metastatic cancer, or on anti-cancer treatment in any setting 104 
(curative/radical/adjuvant/neoadjuvant setting) or treated within the past 12 months with surgery/cytotoxic 105 
chemotherapy/radiotherapy. Stage of tumour was divided into those into those that were Primary Tumour 106 
Localized- localized to organ and therefore potentially resectable, Primary Tumour- locally advanced- 107 
where it had spread locally from the primary organ and not resectable, Metastatic- where there is distant 108 
spread (stage 4) and those presently in Remission. Patients were assessed as to whether they had 109 
received chemotherapy (which did not include denosumab), immunotherapy, hormonal therapies or 110 
radiotherapy within 4 weeks of contraction of SARS-CoV-2. Non-palliative chemotherapy was defined as 111 
chemotherapy that was used in a neoadjuvant/adjuvant/radical setting. For the purposes of the present 112 
analysis, outcomes were monitored up to April 26th 2020.  113 
 114 
 115 
Data Collection  116 
Prospective data collection was performed by the newly formed pan-UK cancer centre emergency 117 
response network. Case reporting was led by a COVID-19 Emergency Response Reporting Individual 118 
(ERRI), supported by a Local Emergency Response Reporting Group (LERRG) at each centre. The role 119 
of the LERRG was to ensure near continuous reporting of cases in situations of absence of the ERRI due 120 
to off-days, illness, compassionate leave, self-isolation or re-deployment. The UKCCMP encouraged all 121 
local reporting sites to enter data in a real time basis, as soon as a positive SARS-CoV-2 test had been 122 
identified. The data fields were then re-updated as soon as treatment and outcomes had been identified 123 
and also to reflect the worse COVID-19 severity scores during hospitalization. The ERRI was a trained/in 124 
training oncologist who performed data review, annotation and entry. In a small number of centres, data 125 
entry was performed by data managers but with direct oversight by the ERRI. All registry entries were de-126 
identified at source to ensure data anonymity to researchers. Data was entered into a Research Electronic 127 
Data Capture (REDCap) browser-based metadata driven electronic data capture (EDC) software system. 128 
11 This secure EDC platform is hosted by the Institute of Translational Medicine at the University of 129 
Birmingham. Patient demographics, treatment details, COVID-19 disease course and cancer features 130 
were obtained from the direct assessment of the ERRI/LERRG and/or through hospital medical records. 131 
COVID-19 Severity Score was determined according to the WHO guidelines.12 Cancer type was defined 132 
according to ICD-10 diagnostic codes.  133 
 134 
 135 
UKCCMP data processing and analysis 136 
The data through the REDCap platform is transferred securely through to the Compute and Storage for 137 
Life Science (CaStLeS) infrastructure as part of the Birmingham Environment for Academic Research 138 
local Cloud (BEARCloud) 13 at the Centre for Computational Biology, University of Birmingham.  139 
 140 
Within CaStLeS, the data is curated to avoid duplications and errors, then annotated with further 141 
information such as geolocation before it can be analysed and disseminated. The deployment of an 142 
automatic workflow, with human-in-the-loop, enables near real-time robust data analytics delivery to 143 
oncology medical health professionals through a weekly report in addition to a secured interactive web 144 
portal. Importantly, it enables delivery of national and local analytics with dynamic level of granularity.  145 
 146 
 147 
Statistical analysis & Data visualisation 148 
 149 
In this study, we report on the clinical outcomes of cancer patients who developed COVID-19 disease, 150 
assessing whether the patient died or eventually achieved discharge, and observing the effect of anti-151 
cancer treatment on outcomes. The two-sided Welch’s t-test was used to compare continuous data and 152 
two-sided Fisher’s exact test was used to compare categorical data from different categories with 153 
multivariate Bonferroni (multi-test) adjustment. A primary endpoint of all-cause mortality was defined a 154 
priori. This included deaths described as related to COVID-19 during this admission, as well as deaths 155 
reported as a consequence of any other cause during this admission, such as due to cancer progression 156 
or treatment toxicity. This was used for all regression analyses. Multivariate analyses were performed in 157 
SPSS, version 26 and Fisher’s Exact tests in R version 3.6.3 utilising the Fisher.test () function. 158 
Multivariable logistic regression was used to estimate odd ratios and 95% confidence intervals of each 159 
factor after adjustment for clinically relevant potential confounders of age, sex, diabetes, hypertension, 160 
COPD or other comorbidities at admission. Goodness of fit was checked using Hosmer-Lemeshow test 161 
and, unless otherwise reported, had p>0.05. Where this goodness of fit criteria was not met, further 162 
multivariable logistic regression models using the above potential confounders was performed using a 163 
forward selection of p<0.10. Patients with either ‘no information/missing relevant data’ were not included 164 
in these regression analyses. Sub-group analyses of patients on chemotherapy was performed in order 165 
to better identify risk in this cohort of patients.  This included an analysis of non-palliative vs. palliative 166 
chemotherapy, first line vs. later lines of palliative chemotherapy, palliative chemotherapy vs. no anti-167 
cancer treatment, palliative chemotherapy vs. no recent chemotherapy.  The justification for these 168 
analyses is that the cancer chemotherapy group is heterogenous. These subgroup analyses have a well-169 
established oncology/clinical rationale, for example, non-palliative (curative)  chemotherapy aims to 170 
prevent recurrence or eradicate disease, whereas palliative chemotherapy aims to maintain quality of life, 171 
or extend life usually by a matter of months, and both patient and chemotherapy treatment (drugs, dose 172 
and intensity) necessarily evolve as a patient progresses from 1st line to later lines of chemotherapy. 14 173 
Data processing and visualisation utilised R (version 3.6.3) packages. 174 
Project funding 175 
This project was funded by the University of Birmingham (data collection and time of JPC, LL, UKCCMP 176 
and GM) and the University of Oxford (RK time). The University of Birmingham had no formal role in 177 
data collection, analysis, interpretation or decision to submit. 178 
 179 
 180 
181 
Results 182 
 183 
Fifty-five Cancer centres had appointed a COVID-19 local emergency response reporting group (LERRG) 184 
and form part of this clinical network of cancer centres. Together this network covered a patient population 185 
of nearly 1.5 million patients who were living with active cancer, with good coverage across all regions of 186 
the United Kingdom (Figure 1).  187 
 188 
This early patient cohort consists of the first 800 patients with active cancer who had a documented SARS-189 
CoV-2 infection presenting as symptomatic COVID-19 disease. As presented in Table 1, 56% of patients 190 
were male with a median age of 69.0 years (IQR 59-76). Comorbidities were common, including 191 
hypertension (n=247, 31%), diabetes (n=131, 16%), cardiovascular disease (n=109, 14%), COPD (n=61, 192 
8%). One hundred and sixty-nine cancer patients were listed as having no comorbidities apart from their 193 
cancer diagnosis (21%). Approximately half of the patients had current ongoing metastatic cancer (n=347, 194 
43%), of which malignant neoplasia of the digestive organs (n=150, 19%), haematological malignancies 195 
(n=109, 14%), breast (n=102, 13%) and respiratory and thoracic organs (n=90, 11%) were the commonest 196 
primary tumour sites. The median time from identification of documented COVID-19 disease until study 197 
end points were met (death or discharge from hospital) was 5 days (range 0-38).  198 
 199 
In terms of the pattern of COVID-19 presentation, most presented with fever (n=484, 61%), cough (n=377, 200 
47%), and/or shortness of breath (n=312, 39%). However, diarrhoea (n=51, 6%), nausea and vomiting 201 
(n=39, 5%), ageuisa (n=13, 2%) and anosmia (n=9, 1%) were also identified as less common presenting 202 
symptoms.  203 
 204 
A number of correlates of severity of COVID-19 were measured, according to WHO criteria. 12  A mild 205 
COVID-19 severity was score was recorded in 412 patients (52%), with 96 patients (12%) not requiring 206 
hospitalization. 315 patients required oxygen (39%), and 53 patients received ITU-level care (7%). Of 207 
these 53 patients, at the time of analysis, 6 were discharged (11%), 23 died (43%) and 24 were either still 208 
in ITU and/or did not have a final recorded outcome (45%). The ITU admission rate was notably low and 209 
reflective of findings from the UK intensive care national audit and research centre (ICNARC) 15.  210 
 211 
Death in this cohort was the final outcome in 226 patients (28%) with reporting stating that the death was 212 
principally attributable to COVID-19 in the majority of these cases (n=211, 93%). This mortality rate is 213 
higher than reported literature in the ‘general’ population, and likely to reflect the relative severity of 214 
symptoms of cancer patients who seek help from secondary care. Compared to the rest of the cancer 215 
cohort, patients who died were significantly older (median 73.0 years vs. 66.0 years, p<0.001) (Figure 2), 216 
more were male (mortality 33%, 146/449) than female (mortality 23%, 80/349) and those who died also 217 
displayed higher rates of comorbidities including cardiovascular disease (21% vs 11%, p<0.001) and 218 
hypertension (41% vs 27%) (p<0.001). They were also more likely to present with symptoms of shortness 219 
of breath (57% vs 32%) (p<0.001).  220 
 221 
Across the cohort, 22% of patients were reported by sites as having their anti-cancer treatments 222 
interrupted due to the COVID-19 pandemic, though, the exact nature of this interruption was not captured 223 
in this study. 224 
 225 
Compared to patients who had not received chemotherapy within 4 weeks of testing positive for COVID-226 
19, those who had received recent chemotherapy did not suffer increased mortality when analysed by 227 
univariate analysis (27% death rate with chemotherapy vs 29% death rate without recent chemotherapy).  228 
 229 
In order to explore this relationship in greater detail, an in-depth analysis of the 281 patients who had 230 
received recent chemotherapy use was therefore performed (Figure 3). There were no significant 231 
differences in underlying cancer primary site in the recent chemo versus no chemo group. However, 232 
compared to cancer patients who had not received recent chemotherapy, the chemotherapy positive 233 
cohort was younger (median age 64.0 years vs. 71.0 p<0.001).  Therefore, a multivariate analysis with 234 
adjustment for age, sex and comorbidities was performed and we found that deaths in COVID-19 cancer 235 
patients who had received recent chemotherapy were still no more likely than those that had not (OR 236 
1.18, 95% CI [0.81 to 1.72]; p=0.380) (Table 2). This analysis had a borderline fit (Hosmer-Lemeshow test 237 
p value=0.048). To be more confident of our findings, we also performed a forward regression model 238 
(Hosmer-Lemeshow goodness of fit p=0.476) with similar findings (OR 1.15, 95% CI [0.79 to 1.66], 239 
p=0.467).  240 
 241 
Patients receiving chemotherapy are a heterogeneous group and so further exploratory subgroup 242 
analyses were performed. On further multivariate analysis of the group of patients who had received 243 
recent chemotherapy, decreased odds of death was found in patients receiving non-palliative 244 
chemotherapy (neoadjuvant/adjuvant/radical) compared to those receiving palliative chemotherapy (16% 245 
vs 35%) (OR 0.40 CI [0.17 to 0.96]; p=0.040) following adjustments for age, sex and comorbidities. 246 
However, the odds of death in these palliative chemotherapy patients was still not significantly different to 247 
cancer patients with no anti-cancer treatment at all (OR 1.05, 95% CI [0.63 to 1.76]; p=0.854), but there 248 
was a non-significant trend compared to those with no recent chemotherapy (OR 1.48, 95% CI [0.93 to 249 
2.36]; p=0.102). There was no significant differences in mortality in those patients receiving first line 250 
palliative chemotherapy compared to those receiving later lines of palliative treatment (OR 0.84, 95% CI 251 
[0.36 to 1.98]; p=0.690) following adjustments for age, sex and comorbidities. 252 
 253 
Finally, we analysed the use of other forms of anti-cancer therapies within 4 weeks of testing positive for 254 
SARS-CoV-2 infection and presenting with COVID-19 disease. Compared to the rest of the cohort who 255 
were not on these therapies, patients on immunotherapy (n=44, OR 0.59, 95% CI [0.27 to 1.27]; p=0.177), 256 
hormonal therapy (n= 64, OR 0.90, 95% CI [0.49 to 1.68]; p=0.744), radiotherapy (n=76, OR 0.65, 95% 257 
CI [0.36 to 1.18]; p=0.159) and targeted therapies (n= 72, OR 0.83, 9% CI [0.45 to 1.54]; p=0.559) were 258 
also not at any additional risk of death following adjustment for age, sex and comorbidities (Figure 4).  259 
 260 
 261 
  262 
Discussion 263 
 264 
Global healthcare systems are currently dealing with the COVID-19 pandemic, a disease caused by 265 
SARS-CoV-2 infection; a situation which is set to be a generational challenge to all clinicians. At the time 266 
of writing, the clinical phenotype and interactions of SARS-CoV-2 infection/ COVID-19 disease with pre-267 
existing disease and systemic anti-cancer treatments agents is poorly described and based on very small 268 
retrospective studies. 269 
 270 
The disruption from the pandemic to normal oncological care has been huge for a number of reasons. 271 
Firstly, cancer clinicians and the rest of the cancer team are under unprecedented pressures, with 272 
increasing concern from patients about their perceived ‘vulnerability’, cancelled cancer operations, a 273 
significant drive to do telemedicine rather than face to face consultations, and a high degree of absence 274 
from work across the cancer team, due to personal illness and self / household isolation. Secondly, many 275 
oncologists are being redeployed to general or acute medicine roles to support the large number of 276 
COVID-19 admissions requiring intensive medical support and input. Thirdly, a couple of small studies 277 
reporting COVID-19 outcomes in cancer patients has resulted in the community being fearful of giving 278 
effective anticancer treatments. These studies concluded that cancer patients are not only more 279 
susceptible to contracting the virus, but also at risk of developing more severe sequelae.3,2 In the largest 280 
cohort of 105 cancer patients consisting of only 17 on chemotherapy, 6 patients on immunotherapy and 281 
4 on targeted therapies, strong recommendations were made about the COVID-19 risk from anti-cancer 282 
treatments.1 All of these studies are small cohorts and limited to a very restricted number of cancer centres. 283 
We felt that the studies raised important hypotheses but were in no way unequivocal and indeed there 284 
are contradictory studies from a single centre study from the United States of America. 16 To clarify the 285 
relationship between cancer, anti-cancer treatments and COVID-19 infection, it is clear that larger-scale 286 
datasets are necessary. 287 
 288 
Because of the limited prevalence of the coexistence of cancer and COVID-19 disease, individual health 289 
care centres and physicians will only encounter small numbers of patients with both diseases. In addition, 290 
because of the fire-fighting nature of pandemic healthcare, much of the usual infrastructure of medical 291 
professional data dissemination has been completely dismantled: local, national, and international clinical 292 
meetings have been delayed or cancelled as part of public health measures to prevent COVID-19 spread. 293 
It is therefore of even greater importance that national and international strategies to share data quickly 294 
and effectively are created during this time of unprecedented need for rapid learning and evidence 295 
regarding best practice. 296 
 297 
The UKCCMP was designed to serve as a Public Health Surveillance registry to answer important 298 
questions about the interaction of cancer, its treatments and COVID-19, and to support rapid clinical 299 
decision-making. Close alignment of healthcare systems, physicians, and patients has meant that the 300 
project was launched and produced clinically meaningful output over the course of four weeks. 301 
 302 
In this paper, the UKCCMP describes the demographics of cancer patients with COVID-19 and explores 303 
the effect of cytotoxic chemotherapy and other anti-cancer treatments on the trajectory of that disease. 304 
We have identified that the phenotype of diagnosed COVID-19 disease in over half of cancer patients is 305 
mild, but death from COVID-19 in this cohort was observed in a significant percentage of patients. This 306 
mortality is higher than that observed in the general non-cancer UK population, 17 and may be  reflective 307 
of the severity of symptoms of the cancer patients who choose to seek treatment in secondary healthcare 308 
setting. It is interesting to note that the rate of admission to ITU was low at about 6% compared to a death 309 
rate of approximately 28%. Our dataset is currently unable to answer the question as to whether this might 310 
arise as a result of advance patient healthcare directives, hospital/ITU admission policy, a reluctance of 311 
treating physicians to utilise ITU resources for cancer patients or historically lower numbers of ITU beds 312 
available in the United Kingdom 18. This does raise questions as to whether having a diagnosis of cancer 313 
decreases the potential access of these patients to the most intensive support. 314 
 315 
From this early dataset, using multivariate analysis, we conclude that cytotoxic chemotherapy given within 316 
4 weeks prior to confirmed COVID-19 disease is not a significant contributor to a more severe disease or 317 
a predictor of death from COVID-19, compared to cancer patients who have not received chemotherapy 318 
in that period. Whilst numbers are smaller, similar observations were observed for immunotherapy, 319 
hormonal therapy, targeted therapy and radiotherapy. Again, further interrogation with higher numbers 320 
will allow us to confirm or refute this finding.  321 
 322 
Overall, in interpreting these data, and putting them into context, we suggest that it is important to continue 323 
to shield cancer patients from exposure to SARS-CoV-2, though self-isolation, minimising hospital visits 324 
where they can be avoided (which may mean a substitution or more oral agents in place of intravenous 325 
drugs), avoiding the mixing of COVID negative and COVID positive workstreams within the hospital 326 
environment; and by mitigating the risk of neutropenia to avoid the risk of simultaneous COVID-19 and 327 
bacterial septicaemia. It is also important to ensure that cancer patients have equivalent access to ITU 328 
care. However, in answer to the frequent question from patients as to whether chemotherapy or anti-329 
cancer treatments will increase their risk of dying from COVID-19, in addition to the increased risk due to 330 
their cancer, our answer should be, not necessarily so. In patients presenting to NHS trusts or cancer 331 
centres, our data is strongly indicative that cancer COVID-19 mortality is principally driven by advancing 332 
age and the presence of other non-cancer co-morbidities. We conclude that withholding effective cancer 333 
treatments from significant numbers of cancer patients during the current pandemic runs the very real risk 334 
of increasing cancer morbidity and mortality, perhaps much more so than COVID-19 itself. 335 
 336 
It is important to note the current limitations of the UKCCMP. Our analysis is partly dependent on the UK 337 
national COVID-19 testing policy, which is currently is less permissive than other nations 19,20 and also 338 
relies on RT-PCR which has a well described false negative result. 21 The project may therefore 339 
underreport total COVID-19 cases in cancer patients, particularly those with no/mild symptoms and who 340 
do not require or present to healthcare centres. On the other hand, because we are in such close and 341 
frequent contact with our patients, and have a high index of suspicion on their behalf, we may also repeat 342 
testing and potentially over report SARS-CoV-2 infection compared to the general population. One might 343 
argue that there could be a selection bias, in that those patients that were not on chemotherapy may have 344 
been taken off because of a poorer performance status, thus increasing their risk of death from COVID-345 
19 disease, and reducing our ability to assess the real risk of anticancer treatments in a better performance 346 
status ‘healthier’ population. However, we have attempted to address this through multivariate analyses 347 
with age and co-morbidity correction. Finally, we do not comment on overall incidence of COVID-19 348 
positivity amongst cancer patients because we do not yet have secure numerators and denominators for 349 
that calculation. However, total number of cases remain thankfully low, likely reflecting effective cancer 350 
social isolation policies.  351 
 352 
Despite these noted limitations, the UKCCMP is unique in covering the majority of the UK cancer 353 
population, with universal access to cancer care and has been achieved through the rapid set up of a 354 
dedicated and coordinated emergency cancer network. The UKCCMP will continue to update our data 355 
weekly and share our outcomes with the oncological community.  356 
 357 
With greater numbers analysed we will be able to answer more nuanced questions and guide further 358 
research. It will be important to investigate if the grading of COVID-19 could be further refined, to add 359 
granularity to our understanding the heterogeneity between different tumour subtypes, to clarify the risks 360 
of specific anti-cancer treatments, to determine if there are risks relating to more specific timing of anti-361 
cancer treatments, and to gain a better understanding of the interaction between the host immune 362 
response and risk from COVID-19. There are some very interesting questions surrounding the differential 363 
impact of various anticancer treatments on different components of the immune system (neutrophils, 364 
cytotoxic T-cells, regulatory T cells and macrophages) and how these will interplay with the risk of 365 
contracting SARS-CoV-2 infection, or with the possibility of severe COVID-19 disease sequelae such as 366 
the cytokine storm. 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
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 387 
 388 
 389 
 390 
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 402 
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 405 
 406 
Table 1: Clinical features of patients in the UKCCMP registry, 16th April 2020, with breakdown by 407 
all- cause mortality. Data are displayed as number of cases, except for age which is median age.  408 
 409 
Patient features  All patients (n=800)  Patients Died (n=226) 
Patients Survived 
(n=574) 
Sex and age         
‐ Male  449 (56%) 146 (65%)  303 (53%) 
‐ Female  349 (44%) 80 (35%)  269 (47%) 
‐ Othera  2 (0%) 0 (0%)  2 (0%) 
‐ Median age/years   69 73  66 
Co‐morbidities         
‐ Cardiovascular disease  109 (14%) 48 (21%)  61 (11%) 
‐ COPD  61 (8%) 24 (11%)  37 (6%) 
‐ Diabetes  131 (16%) 46 (20%)  85 (15%) 
‐ Hypertension  247 (31%) 92 (41%)  155 (27%) 
‐ None  169 (21%) 27 (12%)  142 (25%) 
‐ Otherb  336 (42%) 108 (48%)  228 (40%) 
‐ No information  123 (15%) 28 (12%)  95 (17%) 
Cancer type         
‐ Lip, oral cavity and pharynx  27 (3%) 4 (2%)  23 (4%) 
‐ Digestive organs  150 (19%) 42 (19%)  108 (19%) 
‐ Respiratory and intrathoracic organs  90 (11%) 32 (14%)  58 (10%) 
‐ Melanoma (Skin)  27 (3%) 4 (2%)  23 (4%) 
‐ Breast  102 (13%) 18 (8%)  84 (15%) 
‐ Female genital organs  45 (6%) 5 (2%)  40 (7%) 
‐ Male genital organs  78 (10%) 30 (13%)  48 (8%) 
‐ Urinary tract  50 (6%) 16 (7%)  34 (6%) 
‐ Central nervous system  15 (2%) 3 (1%)  12 (2%) 
‐ Lymphoma  60 (8%) 20 (9%)  40 (7%) 
‐ Other Haematological  109 (14%) 40 (18%)  69 (12%) 
‐ Otherc/unspecified  47 (6%) 12 (5%)  35 (6%) 
Cancer Stage         
‐ Primary Tumour ‐ Localised  149 (19%) 40 (18%)  109 (19%) 
‐ Primary Tumour ‐ Locally Advanced  78 (10%) 14 (6%)  64 (11%) 
‐ Metastatic  347 (43%) 103 (46%)  244 (43%) 
‐ Remission  21 (3%) 3 (1%)  18 (3%) 
‐ No information  205 (25%) 66 (29%)  139 (24%) 
Cancer treatment within 4 weeks         
‐ Chemotherapy  281 (35%) 75 (33%)  206 (36%) 
‐ Hormone Therapy  64 (8%) 21 (9%)  43 (7%) 
‐ Immunotherapy  44 (6%) 10 (4%)  34 (6%) 
‐ Radiotherapy  76 (10%) 18 (8%)  58 (10%) 
‐ Surgery  29 (4%) 7 (3%)  22 (4%) 
‐ Targeted Treatment  72 (9%) 16 (7%)  56 (10%) 
‐ Otherd  60 (8%) 13 (6%)  47 (8%) 
‐ None  272 (34%) 92 (41%)  180 (31%) 
‐ No information   10 (1%) 1 (0%)  9 (2%) 
COVID‐19 Severity Score         
‐ Mild  412 (52%) 22 (10%)  390 (68%) 
‐ Severe  187 (23%) 59 (26%)  128 (22%) 
‐ Critical  173 (22%) 140 (62%)  33 (6%) 
‐ No information  28 (3%) 5 (2%)  23 (4%) 
COVID‐19 treatment         
‐ ITU  53 (7%) 23 (10%)  30 (5%) 
 a Patient features- other, identifies patient where the patient does not identify as either male/female 410 
b Co-morbidities- other, identifies co-morbidities which are not any of the co-morbidities included in the tables 411 
c Cancer type- other, identifies ICD10 cancer types including malignant neoplasia of the bone and articular tissue, 412 
endocrine glands, mesothelioma and soft tissue and any other tumour type which was not included in the table.  413 
d Cancer type- other, identifies cancer treatments which do not fall into the cancer treatment types defined in the table  414 
Table 2: Regression analysis and odds of death based on features of patients in the UKCCMP. 415 
Univariate analysis was conducted with presence compared to absence (reference) for each 416 
category except for sex and age. Male sex was compared with reference to female sex. A 417 
Bonferroni p-value adjustment was performed. Multivariate analysis was conducted correcting for 418 
age, sex and patient co-morbidities.  419 
 420 
Patient features 
Univariate analysis 
p value p adjusted 
 
Odds Ratio (95% CI) 
 
Sex and age        
- Sex 1.67 (1.19-2.34) 0.003 0.006 ** 
- Age 9.42 (6.56-10.02) <0.0001 <0.0001 **** 
Co-morbidities       
- Cardiovascular disease 2.32 (1.47-3.64) 0.0003 0.0019 ** 
- COPD 1.80 (1.00-3.27) 0.063 ns  
- Diabetes 1.61 (1.03-2.48) 0.032 ns  
- Hypertension 1.95 (1.36-2.80) 0.0003 0.0015 ** 
Cancer type        
- Lip, oral cavity and pharynx 0.42 (0.13-1.21) 0.116 ns  
- Digestive organs 0.91 (0.60-1.38) 0.680 ns  
- Respiratory and intrathoracic organs 1.50 (0.91-2.45) 0.121 ns  
- Melanoma (Skin) 0.37 (0.12-1.14) 0.079 ns  
- Breast 0.48 (0.28-0.84) 0.009 ns  
- Female genital organs 0.31 (0.11-0.81) 0.010 ns  
- Male genital organs 1.99 (1.14-3.48) 0.015 ns  
- Urinary tract 1.10 (0.58-2.12) 0.745 ns  
- Central nervous system 0.64 (0.15-2.32) 0.760 ns  
- Lymphoma 1.30 (0.71-2.30) 0.373 ns  
- Other Haematological 1.57 (1.01-2.42) 0.040 ns  
Cancer Stage     
- Primary Tumour - Localised 1.04 (0.67-1.64) 0.912 ns 
- Primary Tumour - Locally Advanced 0.58 (0.29-1.09) 0.111 ns 
- Metastatic 1.34 (0.90-2.01) 0.145 ns  
- Remission 0.42 (0.10-1.43) 0.204 ns  
Cancer treatment within 4 weeks        
- Chemotherapy 0.78 (0.55-1.11) 0.173 ns  
- Hormone Therapy 1.16 (0.64-2.06) 0.659 ns  
- Immunotherapy 0.60 (0.27-1.24) 0.179 ns  
- Radiotherapy 0.66 (0.37-1.17) 0.178 ns  
- Surgery 0.83 (0.32-2.15) 0.825 ns  
- Targeted Treatment 0.56 (0.30-1.01) 0.058 ns  
COVID-19 Severity Score       
- Mild 0.03 (0.02-0.05) <0.0001 <0.0001 **** 
- Severe 1.63 (1.10-2.40) 0.015 0.045 * 
- Critical 89.65 (41.64-209.83) <0.0001 <0.0001 **** 
COVID-19 treatment        
- ITU 
 
1.95 (1.09-3.52) 
 0.027 0.027 
* 
 
Treatment features Multivariate analysis 
p value    
  Odds Ratio (95% CI)  
Recent ant-cancer treatments       
- Chemotherapy vs no chemotherapy 1.18 (0.81-1.72) 0.380   
- Hormone therapy vs no hormone Therapy 0.90 (0.49-1.68) 0.744   
- Immunotherapy vs no Immunotherapy 0.59 (0.27-1.27) 0.177   
- Radiotherapy vs no radiotherapy 0.65 (0.36-1.18) 0.159   
-Targeted treatment vs no targeted treatment 0.83 (0.45-1.54) 0.559   
Cytotoxic Chemotherapy       
-Non-palliative chemo vs palliative chemo 0.40 (0.17-0.96) 0.040   
-Palliative 1st line chemo vs other line 0.84 (0.36-1.98) 0.690   
-Palliative chemo vs no chemo 1.48 (0.93-2.36) 0.102   
-Palliative chemo vs no treatment 1.05 (0.63-1.76) 0.854   
 421 
* denotes statistical significance of p adjusted, where * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 422 
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FIGURE LEGENDS 515 
 516 
 517 
Figure 1: Geographical plot, 26th April 2020, demonstrating the prevalence of COVID-19 in the Scotland, 518 
Wales and regions of England. Data displayed is average number of cases from reports per cancer centre 519 
region.  520 
 521 
Figure 2: Horizontal bar plot demonstrating the age distribution of cancer patients in the cohort and relation 522 
to patient mortality.  523 
 524 
Figure 3: Sankey plot demonstrating relationship of chemotherapy use within 4 weeks of contracting 525 
COVID-19 infection and mortality and severity of disease course. The vertical coloured bars denote the 526 
patient cohort, split into different groups (purple- severity of COVID19, blue- presence or absence of 527 
recent chemotherapy, red/green-patient mortality). The grey horizontal bars denote that associations 528 
between the different groups with wider bars denoting more overlap. 529 
 530 
Figure 4: Forest plots showing effect of anti-cancer treatments and mortality from COVID-19 infection 531 
 532 
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 544 
Supplementary Methods 545 
 546 
Data visualisation and figure generation 547 
Data processing and visualisation utilised R (version 3.6.3) packages including broom, dplyr, gpclib, 548 
ggmap, ggplot2, mapdata, maps, maptools, networkD3, rgdal, rgeos, robustbase and viridis. Data 549 
subsetting was performed using the subset() function of ‘robustbase’ and data reshaping for visualisation 550 
involved the use of the group_by() and melt() functions of ‘dplyr’. Functions from the ggplot2 R package 551 
were used to generate multiple plots including barplots (geom_bar) and UK region map (geom_polygon). 552 
The sankeyNetwork() function of the ‘networkD3’ R package was also used to generate the Sankey plot. 553 
The shape (.shp) file for the UK region map was publicly available from the UK Office for National 554 
Statistics. 22 555 
 556 
